Related Experiment Videos
Evaluation of a new bladder tumor marker.
H B Grossman1, M Liebert, N Sakakibara
1Department of Surgery, University of Michigan, Ann Arbor.
The Urologic Clinics of North America
|August 11, 1991
Summary
Researchers developed monoclonal antibodies targeting a shed bladder tumor antigen. Positive tumors release this antigen into urine, unlike negative tumors, suggesting its potential as a diagnostic marker for bladder cancer.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Bladder cancer diagnosis often relies on invasive procedures.
- There is a need for non-invasive biomarkers for early detection and monitoring.
- Tumor-associated antigens are potential candidates for cancer diagnostics.
Purpose of the Study:
- To develop and characterize monoclonal antibodies against a shed bladder tumor-associated antigen.
- To evaluate the antigen's presence in urine as a potential diagnostic marker for bladder cancer.
- To investigate differential metabolism of the antigen by normal and malignant urothelial cells.
Main Methods:
- Development of two specific monoclonal antibodies.
- Detection of shed antigen in urine samples.
- Comparative analysis of antigen shedding in antigen-positive versus antigen-negative tumors.
- Investigation of antigen metabolism in different cell types.
Main Results:
- Two monoclonal antibodies successfully bind to a shed bladder tumor-associated antigen.
- Preliminary data show detectable antigen levels in the urine of patients with antigen-positive tumors.
- Antigen-negative tumors do not shed detectable amounts of the antigen.
- Evidence suggests differential metabolism of the antigen by normal and malignant urothelial cells.
Conclusions:
- The shed bladder tumor-associated antigen shows promise as a urinary biomarker.
- Further research is warranted for its clinical evaluation in diagnosing antigen-positive bladder cancers.
- Understanding antigen metabolism may provide further insights into bladder cancer biology.